RecruitingNot ApplicableNCT05994859

SIRT for Potentially Resectable HCC

Y-90 Selective Internal Radiation Therapy for Potentially Resectable Hepatocellular Carcinoma: a Prospective, Single Arm Trial


Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Enrollment

35 participants

Start Date

Aug 10, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This study is conducted to evaluate the efficacy and safety of Y-90 selective internal radiation therapy (SIRT) in patients with potentially resectable hepatocellular carcinoma (HCC).


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether SIRT (selective internal radiation therapy — tiny radioactive beads injected directly into liver tumor blood vessels) can shrink liver cancer enough to make it operable for patients whose tumors cannot currently be removed with surgery. **You may be eligible if...** - You have liver cancer (HCC) confirmed by biopsy or clinical diagnosis - You have not received any previous treatment for liver cancer - Your tumor is confined to one side of the liver and may be potentially removable after downsizing - Your liver is functioning well (Child-Pugh Class A) or you do not have cirrhosis - You are in good overall health (ECOG 0–1) **You may NOT be eligible if...** - You have already received treatment for liver cancer - Your cancer has spread to both lobes of the liver or to other organs - Your liver function is poor Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURESIRT

The patients will receive 1-2 sessions of SIRT. If the patients have invasive tumors, extensive liver involvement or vascular invasion, systematic treatment will be added.


Locations(1)

The Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05994859


Related Trials